S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Our #1 Small-Cap Stock for [MONTH] (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
Retirees Face “Income Destruction” (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Most profitable less than $5 stock in the world? (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Our #1 Small-Cap Stock for [MONTH] (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
Retirees Face “Income Destruction” (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Most profitable less than $5 stock in the world? (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Our #1 Small-Cap Stock for [MONTH] (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
Retirees Face “Income Destruction” (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Most profitable less than $5 stock in the world? (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Our #1 Small-Cap Stock for [MONTH] (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
Retirees Face “Income Destruction” (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Most profitable less than $5 stock in the world? (Ad)pixel
NASDAQ:ARDX

Ardelyx - ARDX News Headlines

$0.89
-0.02 (-2.19%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.88
$0.93
50-Day Range
$0.51
$0.91
52-Week Range
$0.49
$1.92
Volume
2.39 million shs
Average Volume
3.03 million shs
Market Capitalization
$138.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.20
Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

ARDX Media Mentions By Week

ARDX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARDX
News Sentiment

0.31

0.48

Average
Medical
News Sentiment

ARDX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARDX Articles
This Week

16

4

ARDX Articles
Average Week



SourceHeadline
marketbeat.com logoFY2026 Earnings Estimate for Ardelyx, Inc. Issued By Wedbush (NASDAQ:ARDX)
marketbeat.com - August 8 at 4:23 AM
marketbeat.com logoArdelyx (NASDAQ:ARDX) Given "Neutral" Rating at Wedbush
marketbeat.com - August 6 at 7:34 AM
marketbeat.com logoArdelyx (NASDAQ:ARDX) Releases Quarterly Earnings Results, Meets Expectations
marketbeat.com - August 5 at 2:55 PM
finance.yahoo.com logoPrimary Care Providers Report a High Unmet Need for New Therapeutic Treatment Options for Chronic Kidney Disease, Despite Earlier Intervention and Referrals to Nephrologists, Spherix Reports - Yahoo Finance
finance.yahoo.com - August 10 at 3:13 PM
MarketBeat logoBrokers Set Expectations for Ardelyx, Inc.'s FY2026 Earnings (NASDAQ:ARDX)
americanbankingnews.com - August 9 at 3:56 AM
MarketBeat logoWedbush Reiterates Neutral Rating for Ardelyx (NASDAQ:ARDX)
americanbankingnews.com - August 9 at 1:22 AM
MarketBeat logoStockNews.com Downgrades Ardelyx (NASDAQ:ARDX) to Sell
americanbankingnews.com - August 8 at 1:30 AM
seekingalpha.com logoArdelyx, Inc. (ARDX) CEO Michael Raab on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 2:11 AM
finance.yahoo.com logoArdelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
finance.yahoo.com - August 4 at 4:16 PM
MarketBeat logoAnalysts Set Ardelyx, Inc. (NASDAQ:ARDX) Target Price at $4.83
americanbankingnews.com - August 4 at 3:48 AM
benzinga.com logoArdelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference - Benzinga
benzinga.com - August 3 at 10:49 AM
finance.yahoo.com logoArdelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 2 at 2:09 PM
benzinga.com logoArdelyx to Report Second Quarter 2022 Financial Results on August 4, 2022 - Benzinga
benzinga.com - July 28 at 11:42 AM
finance.yahoo.com logoArdelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
finance.yahoo.com - July 28 at 11:42 AM
MarketBeat logoArdelyx, Inc. (NASDAQ:ARDX) Forecasted to Post FY2022 Earnings of ($0.68) Per Share
americanbankingnews.com - July 26 at 2:22 AM
benzinga.com logoSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ardelyx, Inc. - Benzinga - Benzinga
benzinga.com - July 23 at 2:37 AM
MarketBeat logoArdelyx (NASDAQ:ARDX) Shares Pass Below 200-Day Moving Average of $0.80
americanbankingnews.com - July 21 at 3:10 AM
nasdaq.com logoThe past five years for Ardelyx (NASDAQ:ARDX) investors has not been profitable - Nasdaq
nasdaq.com - July 20 at 11:54 PM
finance.yahoo.com logoArdelyx (NASDAQ:ARDX) shareholders have endured a 88% loss from investing in the stock five years ago
finance.yahoo.com - July 20 at 8:11 AM
seekingalpha.com logoArdelyx secures $20M financial deal on tenapanor potential sale (NASDAQ:ARDX) - Seeking Alpha
seekingalpha.com - July 1 at 12:55 AM
streetinsider.com logo3 Penny Stocks To Watch While The Stock Market Is Down - StreetInsider.com
streetinsider.com - June 30 at 2:54 PM
finance.yahoo.com logoArdelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners - Yahoo Finance
finance.yahoo.com - June 30 at 2:54 PM
benzinga.com logoArdelyx Announces FDA Advisory Committee Meeting To Review XPHOZAH NDA Tentatively Scheduled for November - Benzinga
benzinga.com - June 21 at 6:44 PM
seekingalpha.com logoArdelyx stock rises ~13% as kidney disease drug gets FDA panel meeting in November - Seeking Alpha
seekingalpha.com - June 21 at 6:44 PM
finance.yahoo.com logoArdelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
finance.yahoo.com - June 21 at 8:32 AM
uk.finance.yahoo.com logoHyperphosphatemia Treatment Global Market Report 2022 - Yahoo Finance UK
uk.finance.yahoo.com - June 8 at 5:16 PM
finance.yahoo.com logoHyperphosphatemia Treatment Global Market Report 2022 - Yahoo Finance
finance.yahoo.com - June 7 at 9:09 AM
benzinga.com logoArdelyx to Present at the Jefferies 2022 Healthcare Conference - Benzinga - Benzinga
benzinga.com - June 3 at 8:32 AM
finance.yahoo.com logoArdelyx to Present at the Jefferies 2022 Healthcare Conference
finance.yahoo.com - June 3 at 8:32 AM
finance.yahoo.com logoArdelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
finance.yahoo.com - May 24 at 5:44 PM
benzinga.com logoPiper Sandler Maintains Neutral on Ardelyx, Lowers Price Target to $3 - Benzinga - Benzinga
benzinga.com - May 19 at 7:55 AM
finance.yahoo.com logoArdelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022 - Yahoo Finance
finance.yahoo.com - May 17 at 8:36 PM
finance.yahoo.com logoArdelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
finance.yahoo.com - May 17 at 8:36 PM
finance.yahoo.com logoSpherix Global Insights Identifies Significant Unmet Need and Strong Opportunity for a Newly Launched Mechanism of Action in IBS-C Market - Yahoo Finance
finance.yahoo.com - May 14 at 4:56 PM
seekingalpha.com logoArdelyx falls as downgraded to Neutral at Cantor Fitzgerald - Seeking Alpha
seekingalpha.com - May 8 at 1:55 PM
finance.yahoo.com logoArdelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights - Yahoo Finance
finance.yahoo.com - May 6 at 4:54 PM
benzinga.com logoCantor Fitzgerald Downgrades Ardelyx to Neutral - Benzinga - Benzinga
benzinga.com - May 6 at 6:53 AM
finance.yahoo.com logoArdelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
finance.yahoo.com - May 5 at 5:55 PM
seekingalpha.com logoArdelyx: Speculative Biotech With Minimal Downside Risk For Time Being - Seeking Alpha
seekingalpha.com - April 29 at 1:50 PM
benzinga.com logoArdelyx to Report First Quarter 2022 Financial Results on May 5, 2022 - Benzinga - Benzinga
benzinga.com - April 28 at 10:08 AM
finance.yahoo.com logoArdelyx to Report First Quarter 2022 Financial Results on May 5, 2022
finance.yahoo.com - April 28 at 10:08 AM
marketwatch.com logoArdelyx Shares Rally Premarket as FDA Plans Panel Meeting on Xphozah Appeal - MarketWatch
marketwatch.com - April 25 at 6:45 PM
streetinsider.com logoPre-Open Stock Movers 04/25: PS Business Parks and Twitter Jump on Deal News; Axsome Sinks on Expected CRL (more...) - StreetInsider.com
streetinsider.com - April 25 at 1:45 PM
benzinga.com logoFDA Plans To Convene AdComm For Ardelyx's Tenapanor For CKD Patients On Dialysis - Benzinga - Benzinga
benzinga.com - April 25 at 1:45 PM
finance.yahoo.com logoArdelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
finance.yahoo.com - April 25 at 1:45 PM
seekingalpha.com logoARDX stock spikes amid hopes for AdCom meeting on kidney disease drug (NASDAQ:ARDX) - Seeking Alpha
seekingalpha.com - April 25 at 8:44 AM
benzinga.com logoThinking about buying stock in ToughBuilt Industries, Ardelyx, Nkarta, Erytech Pharma, or BigBear.ai? - B - Benzinga
benzinga.com - April 25 at 8:44 AM
globenewswire.com logoLifshitz Law Firm, PC Announces Investigations of Ardelyx Inc. (NASDAQGM: ARDX), Hyzon Motors Inc. (NASDAQ: HYZN), View, Inc. (NASDAQGM: VIEW). and Zymergen Inc. (NASDAQGS: ZY) - GlobeNewswire
globenewswire.com - April 13 at 3:38 PM
finance.yahoo.com logoKyowa Kirin To Cut Royalty Payment Rate To Ardelyx For Tenapanor In Cardiorenal Disorders
finance.yahoo.com - April 11 at 6:29 PM
finance.yahoo.com logoArdelyx and Kyowa Kirin Amend License Agreement for Tenapanor
finance.yahoo.com - April 11 at 9:17 AM
benzinga.com logoArdelyx Presents Data It Says Further Supports Efficacy And Safety Of XPHOZAH (tenapanor) At National Kidney Foundation 2022 Spring Clinical Meetings - Benzinga
benzinga.com - April 7 at 12:06 PM
finance.yahoo.com logoArdelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings
finance.yahoo.com - April 7 at 12:06 PM
finance.yahoo.com logoArdelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
finance.yahoo.com - April 4 at 5:17 PM
Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ARDX) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.